Compare AGYS & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGYS | IDYA |
|---|---|---|
| Founded | 1963 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.6B |
| IPO Year | 1994 | 2019 |
| Metric | AGYS | IDYA |
|---|---|---|
| Price | $114.61 | $41.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $111.67 | $52.86 |
| AVG Volume (30 Days) | 277.3K | ★ 701.7K |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.07 | 61.90 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $319,312,000.00 | $218,710,000.00 |
| Revenue This Year | $17.65 | N/A |
| Revenue Next Year | $14.36 | $201.05 |
| P/E Ratio | $357.81 | ★ N/A |
| Revenue Growth | 15.85 | ★ 3024.43 |
| 52 Week Low | $61.50 | $23.23 |
| 52 Week High | $144.82 | $42.68 |
| Indicator | AGYS | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 73.09 |
| Support Level | $112.83 | $33.23 |
| Resistance Level | $114.23 | N/A |
| Average True Range (ATR) | 3.83 | 1.25 |
| MACD | -0.07 | 0.51 |
| Stochastic Oscillator | 70.94 | 89.03 |
Agilysys Inc is engaged in hospitality software, delivering cloud-native SaaS and on-premise solutions for hotels, multi-amenity resorts, cruise lines, casinos, corporate foodservice management, restaurants, universities, stadiums, and healthcare facilities. The Company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. It operates across the Americas, Europe, the Middle East, Africa, Asia-Pacific, and India with headquarters located in Alpharetta, GA. The Company has one reportable segment serving the global hospitality industry.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.